Inhibition effect produced by dominant negative mutant fusion protein PreS2-TLM-ScFv-HBcDN on HBV replication in vitro

Journal of Viral Hepatitis

Volumn 19, Issue 4, 2012, Pages 295-300

  Liu, W X ^a   Zhu, H H ^a   Wu, W ^a   He, J L ^b   Chen, Z ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

HBc; hepatitis B virus; inhibition effect; PreS2 TLM; pSectag2B; ScFv

Indexed keywords

GENOMIC RNA; HEPATITIS B SURFACE ANTIGEN; PROTEIN PRES2 TRANSLOCATION MOTIF SINGLE CHAIN VARIABLE FRAGMENT EPIDERMAL GROWTH FACTOR; PROTEIN PRES2 TRANSLOCATION MOTIF SINGLE CHAIN VARIABLE FRAGMENT HEPATITIS B VIRUS CORE; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN HEPG2; CELL TRANSFORMATION; CHO CELL; CONTROLLED STUDY; GENETIC TRANSFECTION; HELA CELL; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT; VIRUS INHIBITION; VIRUS MUTANT; VIRUS REPLICATION; WESTERN BLOTTING;

ANTIVIRAL AGENTS; HELA CELLS; HEP G2 CELLS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS;

EID: 84858277948     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01547.x     Document Type: Article

References (24)

1. McMahon BJ,. Natural history of chronic hepatitis B-clinical implications. Medscape J Med 2008; 10: 91.
2. Buster EH, Janssen HL,. Antiviral treatment for chronic hepatitis B virus infection-immune modulation or viral suppression? Neth J Med 2006; 64: 175-185. (Pubitemid 43970918)
3. Lok AS, McMahon BJ,. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857-861. (Pubitemid 38337668)
4. Garcia Buey L, Gonzalez Mateos F, Moreno Otero R,. [Interferon in hepatitis B]. Enferm Infecc Microbiol Clin 2008; 26 (Suppl. 7): 19-31.
5. Scaglioni PP, Melegari M, Wands JR,. Characterization of hepatitis B virus core mutants that inhibit viral replication. Virology 1994; 205: 112-120. (Pubitemid 24360596)
6. Oess S, Hildt E,. Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens. Gene Ther 2000; 7: 750-758. (Pubitemid 30255756)
7. Chu CM, Liaw YF,. Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology 1987; 92: 220-225.
8. Kojima T,. Immune electron microscopic study of hepatitis B virus associated antigens in hepatocytes. Gastroenterol Jpn 1982; 17: 559-575.
9. Sasaki H, Kojima T, Matsui S, et al. Interaction of lymphocytes with hepatocytes containing hepatitis B antigen: ultrastructural demonstration of target antigen and T-cell subsets by the peroxidase antibody technique. Virchows Arch A Pathol Anat Histopathol 1987; 411: 489-498. (Pubitemid 17140667)
10. Wen WH, Qin WJ, Gao H, et al. An hepatitis B virus surface antigen specific single chain of variable fragment derived from a natural immune antigen binding fragment phage display library is specifically internalized by HepG2.2.15 cells. J Viral Hepat 2007; 14: 512-519. (Pubitemid 46944475)
11. Jain M, Chauhan SC, Singh AP, et al. Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors. Cancer Res 2005; 65: 7840-7846. (Pubitemid 41297260)
12. Barka T, Gresik ES, Henderson SC,. Production of cell lines secreting TAT fusion proteins. J Histochem Cytochem 2004; 52: 469-477. (Pubitemid 38420381)
13. Bleifuss E, Kammertoens T, Hutloff A, et al. The translocation motif of hepatitis B virus improves protein vaccination. Cell Mol Life Sci 2006; 63: 627-635.
14. Li J, Chen F, Zheng M, et al. Inhibition of STAT1 methylation is involved in the resistance of hepatitis B virus to Interferon alpha. Antiviral Res 2000; 85: 463-469.
15. Xue F, Dong H, Wu J, et al. Transcriptional responses of Leptospira interrogans to host innate immunity: significant changes in metabolism, oxygen tolerance, and outer membrane. PLoS Negl Trop Dis 2010; 4: e857.
16. Liu MC, Yu M, Zhang NL, et al. Dynamic analysis of hepatitis B virus DNA and its antigens in 2.2.15 cells. J Viral Hepat 2004; 11: 124-129. (Pubitemid 38365762)
17. Dienstag JL,. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500.
18. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695. (Pubitemid 41007823)
19. Kosinska AD, Zhang E, Lu M, et al. Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck. Hepat Res Treat 2010; 2010: 817580.
20. Chiou HC, Lucas MA, Coffin CC, et al. Gene therapy strategies for the treatment of chronic viral hepatitis. Expert Opin Biol Ther 2001; 1: 629-639. (Pubitemid 33769075)
21. Sallberg M, Hughes J, Javadian A, et al. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum Gene Ther 1998; 9: 1719-1729. (Pubitemid 28418742)
22. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419. (Pubitemid 37296260)
23. Schwarzwaelder K, Howe SJ, Schmidt M, et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 2007; 117: 2241-2249. (Pubitemid 47219569)
24. Yi J, Gong WD, Wang L, et al. VP22 fusion protein-based dominant negative mutant can inhibit hepatitis B virus replication. World J Gastroenterol 2005; 11: 6429-6432. (Pubitemid 43136877)